Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-12, Stock:NVS, The news for the past five days is as follows:
2018-10-05: NEWS1: Roche's Hemlibra Receives FDA Approval for Label Expansion.NEWS2: Roche's Hemlibra Receives FDA Approval for Label Expansion.NEWS3: Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data.
2018-10-08: NEWS1: Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick.NEWS2: Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick.NEWS3: Novartis' Applications for MS Drug Accepted by FDA & EMA.NEWS4: Novartis' Applications for MS Drug Accepted by FDA & EMA.NEWS5: Novan scores $11M with partnership with Japanese pharma.NEWS6: Novartis&apos; Applications for MS Drug Accepted by FDA & EMA.NEWS7: Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan.NEWS8: Novartis Announces FDA And EMA Filing Acceptance Of Siponimod.NEWS9: Novartis Announces FDA And EMA Filing Acceptance Of Siponimod.
2018-10-09: NEWS1: Novartis Announces Positive Sickle-cell Pain Trial.NEWS2: Novartis Announces Positive Sickle-cell Pain Trial.NEWS3: Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study.NEWS4: Considering Novartis’s Revenue Growth Rate.NEWS5: How Artificial Intelligence Is Helping Pharmaceuticals Develop Drugs.NEWS6: How Artificial Intelligence Is Helping Pharmaceuticals Develop Drugs.NEWS7: A Look at Novartis’s Valuation on October 9.NEWS8: Assessing Novartis’s Performance in October So Far.NEWS9: In a small San Francisco office, Big Pharma zeroes in on digital health.NEWS10: Pre-Market Most Active for Oct 9, 2018 :  QQQ, PYX, NVS, GE, SQQQ, BABA, TVIX, SNAP, DB, ERIC, TLT, AFMD.NEWS11: Pre-Market Most Active for Oct 9, 2018 :  QQQ, PYX, NVS, GE, SQQQ, BABA, TVIX, SNAP, DB, ERIC, TLT, AFMD.NEWS12: Ionis Pharmaceuticals: Recent Developments and Analysts’ Ratings.
2018-10-10: NEWS1: Novartis Presents Positive Data on Sickle Cell Disease Drug.NEWS2: Novartis Presents Positive Data on Sickle Cell Disease Drug.NEWS3: Novartis Announces Results From Phase IIIb ASSESS Study.NEWS4: Novartis Announces Results From Phase IIIb ASSESS Study.NEWS5: Could Johnson & Johnson Meet Its Q3 2018 Sales Estimates?.NEWS6: Novartis Presents Positive Data on Sickle Cell Disease Drug.NEWS7: Analysts’ Ratings for Johnson & Johnson before Its Q3 Earnings.NEWS8: Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus.NEWS9: Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus.NEWS10: Celgene: Multiple Myeloma Franchise Could Drive Growth.NEWS11: How Novartis’s Sandoz Business Has Been Performing Recently.NEWS12: A Closer Look at Novartis’s Innovative Medicines Segment.NEWS13: The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares.NEWS14: How Novartis’s Businesses Have Been Performing.NEWS15: Novartis To Present 33 Scientific Abstracts.NEWS16: Novartis To Present 33 Scientific Abstracts.
2018-10-11: NEWS1: Abbvie settles Humira patent disputes with Novartis unit.NEWS2: Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes.NEWS3: Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes.NEWS4: AbbVie stock ticks higher as Humira patent dispute with Novartis resolved.NEWS5: Wall Street Analysts See Upside Potential of 3.9% in TEVA.NEWS6: Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales.NEWS7: Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales.NEWS8: Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing.NEWS9: Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing.NEWS10: Novartis Presents Data on Multiple Sclerosis Drug Gilenya.NEWS11: Novartis Presents Data on Multiple Sclerosis Drug Gilenya.NEWS12: Novartis Presents Data on Multiple Sclerosis Drug Gilenya.NEWS13: Analysts’ Estimates and Ratings for Novartis in October.NEWS14: A Look at the Performance of Novartis’s Alcon.

Answer: Rise